Entero Healthcare Solutions Limited (NSE: ENTERO, BSE: 544122) is a Mumbai, Maharashtra-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹8,733 Cr, it ranks #639 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 13 in Pharmaceutical Product Distribution. At ₹1,976.00 (as of 16 Nov 2026), the share price is 7.6% below its 52-week high of ₹2,137.60 and 109.3% above its 52-week low of ₹944.00. The share price is up 80.7% over one year and up 36.0% over three months.
| Current Price | ₹1,976.00 |
|---|---|
| Market Cap | ₹8,733 Cr |
| NSE Symbol | ENTERO |
| BSE Code | 544122 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors > Pharmaceutical Product Distribution |
| P/E Ratio | 74.6 |
| Return on Equity | 8.28% |
| Return on Assets | 4.41% |
| 52-Week Range | ₹944.00 – ₹2,137.60 |
| 1-Year Price Change | +80.7% |
| 3-Month Price Change | +36.0% |
| Beta (1Y) | -0.09 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.enterohealthcare.com |
| Revenue | ₹2,087 Cr |
|---|---|
| Net Profit | ₹61 Cr |
| Net Margin | 2.9% |
| EPS (Basic) | ₹10.47 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Entero Healthcare Solutions Limited reported revenue of ₹2,087 Cr in Q2 FY27, up 32.9% from ₹1,571 Cr in Q2 FY26 and up 7.6% from ₹1,941 Cr in Q1 FY27. It posted a net profit of ₹61 Cr for the quarter, against a net profit of ₹37 Cr in Q2 FY26 (up 66.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,339 Cr (Q4 FY25) to ₹2,087 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,087 Cr | ₹61 Cr | 2.9% |
| Q1 FY27 | ₹1,941 Cr | ₹52 Cr | 2.7% |
| Q4 FY26 | ₹1,910 Cr | ₹45 Cr | 2.4% |
| Q3 FY26 | ₹1,707 Cr | ₹34 Cr | 2.0% |
| Q2 FY26 | ₹1,571 Cr | ₹37 Cr | 2.3% |
| Q1 FY26 | ₹1,404 Cr | ₹30 Cr | 2.2% |
| Q4 FY25 | ₹1,339 Cr | ₹31 Cr | 2.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.40% of Entero Healthcare Solutions Limited's shares as of Sept 2026, against 52.42% in Sept 2025 (−0.02 percentage points). Delivery averaged 45.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Entero Healthcare Solutions Limited engages in the trading of pharmaceutical and surgical products in India. The company offers a range of pharmaceuticals and other healthcare products to retail pharmacies and healthcare practitioners; and healthcare products, including pharmaceutical and nutraceutical products and vaccines; medical devices, such as orthopaedic implants and coronary stents; and hospital consumables comprising examination and surgical gloves, syringes, needles, and sutures to hospitals and clinics. It also provides private label products under the Entero Surgicals private label, such as monitoring devices, nursing and rehabilitation products, and consumables; commercial solutions; and healthcare product distribution solutions, including imports, central warehousing, redistribution, last mile delivery, and connection with the pharmacies, hospitals, and clinics. The company was incorporated in 2018 and is based in Mumbai, India.
1. Trading of Pharmaceutical and Surgical Products-This segment engages in the trading of pharmaceutical and surgical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Trading of Pharmaceutical and Surgical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Entero Healthcare Solutions Limited | ₹8,733 Cr | 74.6 | 8.28% | ₹2,087 Cr | +80.7% |
| Remus Pharmaceuticals Limited | ₹941 Cr | 26.1 | 13.78% | — | +0.6% |
| Health X Platform Limited (Sastasundar Ventures Ltd) | ₹871 Cr | 752.7 | -0.18% | ₹484 Cr | -5.7% |
| Aptus Pharma Limited | ₹837 Cr | 156.8 | — | — | +754.0% |
| Vasa Denticity Limited | ₹797 Cr | 76.5 | 6.68% | ₹87 Cr | -21.4% |
| Bijoy Hans Ltd | ₹523 Cr | — | — | — | +128.4% |
| Speciality Medicines Limited | ₹149 Cr | 11.5 | — | — | — |
| Vijaypd Ceutical Limited | ₹136 Cr | 23 | 9.53% | — | — |
| Royal Sense Limited | ₹39 Cr | 5.6 | — | — | -71.2% |
Listed by market capitalisation. Ratios are shown for context only.
Entero Healthcare Solutions Limited is trading at ₹1,976.00, with a market capitalisation of ₹8,733 Cr.
Entero Healthcare Solutions Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).
Entero Healthcare Solutions Limited has a P/E of 74.6 and a return on equity of 8.28%.
Entero Healthcare Solutions Limited is listed on the NSE under the symbol ENTERO and on the BSE under the scrip code 544122.
Entero Healthcare Solutions Limited's share price is up 80.7% over one year and up 36.0% over three months. Its 52-week range is ₹944.00 to ₹2,137.60.
In Q2 FY27, Entero Healthcare Solutions Limited reported revenue of ₹2,087 Cr and net profit of ₹61 Cr, with basic EPS of ₹10.47 (consolidated, parsed from the company's exchange filing).
Entero Healthcare Solutions Limited reported revenue of ₹2,087 Cr in Q2 FY27, up 32.9% from ₹1,571 Cr in Q2 FY26 and up 7.6% from ₹1,941 Cr in Q1 FY27.
Promoters held 52.40% of Entero Healthcare Solutions Limited's shares as of Sept 2026, against 52.42% in Sept 2025 (−0.02 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.